Genmab reports USD 4.24 billion DARZALEX sales and BofA targets Genmab stock at DKK 2,850

Published on 10/18/2026 at 12:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rina-S produced a 45.90 percent response rate in 109 patients on October 3, 2026. Genmab stock has a DKK 2,850 BofA target.

Clinical milestones shape valuation

DARZALEX sales reached USD 4,239 million in the third quarter of 2026, Genmab said on October 13, 2026.
Rina-S produced a 45.90 percent response rate among 109 patients on October 3, 2026.
BofA raised its Genmab target to DKK 2,850 from DKK 2,500 on October 6, 2026.

Pop-Art-Comic mit Wissenschaftlern, Reagenzgläsern und bunten Sprechblasen — Genmab A/S Biotech-Forschung als bunter Pop-Art-Comic mit Wissenschaftlern, Sprechblasen und Laborutensilien, Aktie DK0010272202, Illustration mit AI erstellt.

Genmab A/S (ISIN DK0010272202) reported USD 4,239 million in DARZALEX sales for the third quarter of 2026 in an announcement dated October 13, 2026. The figure gives investors a fresh measure of the royalty stream supporting the biotechnology company. GlobeNewswire reported that Genmab receives royalties on worldwide DARZALEX sales under its license agreement with Johnson & Johnson.

Clinical data broaden the pipeline

The latest commercial update arrives after clinical evidence for Rina-S, an investigational antibody-drug conjugate. In the October 3, 2026 release, Genmab said the treatment produced a 45.90 percent confirmed response rate among 109 patients with platinum-resistant ovarian cancer, while median duration of response reached 12.10 months. Nasdaq also reported median progression-free survival of 9.50 months.

Three events set the sequence

On October 3, 2026, Rina-S showed a 45.90 percent response rate in 109 treated patients. On October 6, 2026, BofA raised its target to DKK 2,850 from DKK 2,500 after positive epcoritamab data, according to Markets Insider. On October 13, 2026, DARZALEX sales reached USD 4,239 million in the third quarter.

What does the pipeline add?

The answer is diversification beyond one royalty-linked medicine. Rina-S is being tested across four Phase 3 trials, while the October 3 release identified additional Phase 2 studies in lung and gastrointestinal cancers. The company also said its science supports eight approved antibody medicines, giving the pipeline a broader commercial base than the latest DARZALEX figure alone.

Genmab keeps several catalysts visible

For investors, the key comparison is between established royalty income and clinical execution. DARZALEX generated USD 2,528 million of third-quarter sales in the United States and USD 1,711 million elsewhere, while Rina-S still carries development risk because its safety and efficacy have not been established. BofA's DKK 2,850 target therefore reflects a valuation view tied to both current sales and future approvals.

Stock context for investors

Genmab is listed on Nasdaq under the ticker GMAB and is headquartered in Copenhagen. The company develops antibody medicines for cancer and other serious diseases, with its portfolio spanning bispecific antibodies, antibody-drug conjugates and immune-modulating therapies.

The further course of trading is shown by the continuously updated real-time quote of Genmab stock.